These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 27759847

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K, Gascon P, Krendyukov A, Gattu S, Li Y, Harbeck N.
    Ann Oncol; 2018 Jan 01; 29(1):244-249. PubMed ID: 29091995
    [Abstract] [Full Text] [Related]

  • 3. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
    Harbeck N, Gascón P, Krendyukov A, Hoebel N, Gattu S, Blackwell K.
    Oncologist; 2018 Apr 01; 23(4):403-409. PubMed ID: 29317553
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Totality of the evidence at work: The first U.S. biosimilar.
    Holzmann J, Balser S, Windisch J.
    Expert Opin Biol Ther; 2016 Apr 01; 16(2):137-42. PubMed ID: 26634611
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z, Grecea D, Smakal M, Tjulandin S, Bondarenko I, Perjesi L, Illes A, Horvat-Karajz K, Aradi I.
    BMC Cancer; 2019 Feb 06; 19(1):122. PubMed ID: 30727980
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Blackwell K, Gascon P, Jones CM, Nixon A, Krendyukov A, Nakov R, Li Y, Harbeck N.
    Ann Oncol; 2017 Sep 01; 28(9):2272-2277. PubMed ID: 28637287
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy.
    Federman N, Dragomir MD, Kizyma Z, Roganovic J, Bias P, Lammerich A, Ben Arie ZR, Zou L, Hoehn G, Buchner A.
    J Pediatr Hematol Oncol; 2019 Oct 01; 41(7):525-531. PubMed ID: 31274668
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.
    Takano T, Ito M, Kadoya T, Osako T, Aruga T, Masuda N, Miyaki T, Niikura N, Shimizu D, Yokoyama Y, Watanabe M, Tomomitsu M, Aogi K.
    Cancer Med; 2023 Oct 01; 12(20):20242-20250. PubMed ID: 37824431
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I, Frutos Pérez-Surio A, Alcácera MA, Andrés R, Salvador MDT.
    Eur J Clin Pharmacol; 2018 Mar 01; 74(3):315-321. PubMed ID: 29152672
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biosimilars G-CSF versus originator G-CSF in post allotransplant recovery. A case-control study.
    Targhetta C, Baronciani D, Capasso M, Depau C, Tandurella I, Giuseppina Corona M, Angelucci E.
    Am J Hematol; 2016 Feb 01; 91(2):E7-8. PubMed ID: 26596244
    [No Abstract] [Full Text] [Related]

  • 20. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
    Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH.
    Invest New Drugs; 2013 Oct 01; 31(5):1300-6. PubMed ID: 23677653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.